



Telbivudine versus Lamivudine Globe Study: 52 Weeks

Telbivudine versus Lamivudine Globe Study: Design




Telbivudine versus Lamivudine Globe Study: Results

HBeAg-POSITIVE Patients: Week 52 Treatment Response



Telbivudine versus Lamivudine Globe Study: Results

HBeAg-NEGATIVE Patients: Week 52 Treatment Response



Telbivudine versus Lamivudine Globe Study: Conclusions

Conclusions: “Among patients with HBeAg-positive chronic hepatitis B, the rates of therapeutic and histologic response at 1 year were significantly higher in patients treated with telbivudine than in patients treated with lamivudine. In both the HBeAg-negative and the HBeAg-positive groups, telbivudine demonstrated greater HBV DNA suppression with less resistance than did lamivudine.”